Cargando…
Vortioxetine Improves Depressive Symptoms and Cognition in Parkinson’s Disease Patients with Major Depression: An Open-Label Prospective Study
Depression is frequent in Parkinson’s disease (PD) patients, but the evidence for many antidepressant agents to treat it in PD is insufficient. The aim of the present prospective open-label single-arm study (VOPARK, an open-label study of the effectiveness and safety of VOrtioxetine in PARKinson’s d...
Autores principales: | Santos García, Diego, Alonso Losada, Maria Gema, Cimas Hernando, Icíar, Cabo López, Iria, Yáñez Baña, Rosa, Alonso Redondo, Ruben, Paz González, Jose Manuel, Cores Bartolomé, Carlos, Feal Painceiras, Maria José, Íñiguez Alvarado, Maria Cristina, Labandeira, Carmen, García Díaz, Iago |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688230/ https://www.ncbi.nlm.nih.gov/pubmed/36358393 http://dx.doi.org/10.3390/brainsci12111466 |
Ejemplares similares
-
Pain Improvement in Parkinson’s Disease Patients Treated with Safinamide: Results from the SAFINONMOTOR Study
por: Santos García, Diego, et al.
Publicado: (2021) -
Safinamide improves sleep and daytime sleepiness in Parkinson’s disease: results from the SAFINONMOTOR study
por: Santos García, Diego, et al.
Publicado: (2021) -
Safinamide Improves Non-Motor Symptoms Burden in Parkinson’s Disease: An Open-Label Prospective Study
por: Santos García, Diego, et al.
Publicado: (2021) -
Effectiveness of Safinamide over Mood in Parkinson’s Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR
por: Labandeira, Carmen M., et al.
Publicado: (2021) -
Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: Results of the RECONNECT study
por: Christensen, Michael Cronquist, et al.
Publicado: (2022)